Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2020 Apr;17(4):202-203.
doi: 10.1038/s41571-020-0346-6.

Upfront osimertinib - winner takes it all?

Jordi Remon  1 , Gilberto Lopes  2
Affiliations
Comment

Upfront osimertinib - winner takes it all?

Jordi Remon et al. Nat Rev Clin Oncol. 2020 Apr.
No abstract available

PubMed Disclaimer

Comment on

  • Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC.
    Ramalingam SS, Vansteenkiste J, Planchard D, Cho BC, Gray JE, Ohe Y, Zhou C, Reungwetwattana T, Cheng Y, Chewaskulyong B, Shah R, Cobo M, Lee KH, Cheema P, Tiseo M, John T, Lin MC, Imamura F, Kurata T, Todd A, Hodge R, Saggese M, Rukazenkov Y, Soria JC; FLAURA Investigators. Ramalingam SS, et al. N Engl J Med. 2020 Jan 2;382(1):41-50. doi: 10.1056/NEJMoa1913662. Epub 2019 Nov 21. N Engl J Med. 2020. PMID: 31751012 Clinical Trial.

References

    1. Soria, J.-C. et al. Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer. N. Engl. J. Med. 378, 113–125 (2018). - DOI
    1. Ramalingam, S. S. et al. Overall survival with osimertinib in untreated, EGFR-mutated advanced NSCLC. N. Engl. J. Med. 382, 41–50 (2020). - DOI
    1. Hosomi, Y. et al. Gefitinib alone versus gefitinib plus chemotherapy for non-small-cell lung cancer with mutated epidermal growth factor receptor: NEJ009 study. J. Clin. Oncol. 38, 115–123 (2020). - DOI
    1. Wu, Y. L. et al. Overall survival from the AURA 3 phase III study: osimertinib versus platinum-pemetrexed in patients with EGFR T790M advanced NSCLC and progression on prior EGFR TKI. Ann. Oncol. 30, ix157–ix181 (2019). - DOI
    1. Ramalingam, S. S. et al. Mechanisms of acquired resistance to first-line osimertinib: preliminary data from the phase III FLAURA study. Ann. Oncol. https://doi.org/10.1093/annonc/mdy424.063 (2018). - DOI - PubMed - PMC